Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

By C. Turtle, K. Hay, L. Hanafi, Daniel H. Li, S. Cherian, Xueyan Chen, B. Wood, A. Lozanski, J. Byrd, S. Heimfeld and 2 more. Journal of Clinical Oncology, 2017

596 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/de180f5ce42b3ec75723a3287ae2f7a860bb322d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Kochenderfer
2. Jennifer N. Brudno

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno

Citations in the corpus

• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “Toxicities are usually reversible and resolve on their own in most cases, though severe cases may require intensive care [7,9,14,15,20,25,41] and immunosuppressive therapy [7,8,11,25,30,41–43].”